Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$424M |
| 2 |
Bath & Body Works
BBWI
|
+$342M |
| 3 |
Home Depot
HD
|
+$259M |
| 4 |
GE Aerospace
GE
|
+$247M |
| 5 |
Palo Alto Networks
PANW
|
+$214M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LNKD
LinkedIn Corporation
LNKD
|
+$917M |
| 2 |
ARMH
ARM HOLDINGS PLC ADS
ARMH
|
+$396M |
| 3 |
Citigroup
C
|
+$377M |
| 4 |
Sherwin-Williams
SHW
|
+$292M |
| 5 |
Starbucks
SBUX
|
+$260M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 20.46% |
| 2 | Healthcare | 16.66% |
| 3 | Communication Services | 14.21% |
| 4 | Technology | 13.93% |
| 5 | Financials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMDZ
526
DELISTED
Immune Design Corp.
IMDZ
| $2.18M | ﹤0.01% |
168,004
-35,448
| -17% | -$409K |
|
527
RLI Corp
RLI
$5.97B
| $2.16M | ﹤0.01% |
64,724
-2,832
| -4% | -$89.1K |
|
528
IBM
IBM
$214B
| $2.15M | ﹤0.01% |
14,853
-11,756
| -44% | -$1.5M |
|
529
Invesco
IVZ
$13B
| $2.1M | ﹤0.01% |
68,274
-34,598
| -34% | -$998K |
|
530
Danaher
DHR
$140B
| $2.08M | ﹤0.01% |
32,567
+24,109
| +285% | +$1.44M |
|
|
ALPN
531
DELISTED
Alpine Immune Sciences Inc
ALPN
| $2.06M | ﹤0.01% |
123,180
+196
| +0.2% | +$3.92K |
|
532
Glacier Bancorp
GBCI
$6.45B
| $1.95M | ﹤0.01% |
76,519
+2,735
| +4% | +$66.4K |
|
533
Plexus
PLXS
$6.69B
| $1.9M | ﹤0.01% |
47,986
+933
| +2% | +$33.1K |
|
534
General Dynamics
GD
$106B
| $1.9M | ﹤0.01% |
+14,426
| New | +$1.91M |
|
535
Oracle
ORCL
$346B
| $1.82M | ﹤0.01% |
+44,417
| New | +$1.64M |
|
536
Ameriprise Financial
AMP
$48.3B
| $1.79M | ﹤0.01% |
19,039
-9,673
| -34% | -$867K |
|
537
Manhattan Associates
MANH
$9.95B
| $1.79M | ﹤0.01% |
31,480
+1,074
| +4% | +$59.7K |
|
538
Altria Group
MO
$125B
| $1.76M | ﹤0.01% |
28,096
-29,307
| -51% | -$1.77M |
|
539
PTC Therapeutics
PTCT
$6.25B
| $1.72M | ﹤0.01% |
266,280
-757,707
| -74% | -$13.2M |
|
|
ANDV
540
DELISTED
Andeavor
ANDV
| $1.67M | ﹤0.01% |
19,368
-3,160
| -14% | -$271K |
|
541
Acadia Pharmaceuticals
ACAD
$4.45B
| $1.63M | ﹤0.01% |
58,417
-534,789
| -90% | -$11.7M |
|
542
Stanley Black & Decker
SWK
$14.6B
| $1.56M | ﹤0.01% |
14,834
-16,826
| -53% | -$1.63M |
|
|
WBA
543
DELISTED
Walgreens Boots Alliance
WBA
| $1.5M | ﹤0.01% |
17,826
+4,594
| +35% | +$367K |
|
544
Welltower
WELL
$175B
| $1.49M | ﹤0.01% |
+21,510
| New | +$1.39M |
|
545
RBC Bearings
RBC
$18.2B
| $1.43M | ﹤0.01% |
19,527
+646
| +3% | +$40.9K |
|
|
MRTX
546
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.41M | ﹤0.01% |
65,789
+535
| +0.8% | +$12K |
|
547
State Street Energy Select Sector SPDR ETF
XLE
$38.3B
| $1.36M | ﹤0.01% |
43,978
+4,146
| +10% | +$120K |
|
548
Blackrock
BLK
$170B
| $1.36M | ﹤0.01% |
3,994
-2,524
| -39% | -$800K |
|
549
Cummins
CMI
$88.5B
| $1.34M | ﹤0.01% |
+12,192
| New | +$1.18M |
|
|
HF
550
DELISTED
HFF Inc.
HF
| $1.33M | ﹤0.01% |
48,205
+13,780
| +40% | +$367K |
|
Similar funds
Jennison Associates's Q1 2016 Portfolio in Review
As of Q1 2016, Jennison Associates held 710 positions worth $95.3B, down 6.5% from $102B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Jennison Associates's Q1 2016 filing shows 56 new, 303 increased, 241 reduced and 102 closed positions. Its largest new stake was Procter & Gamble: 1,657,581 shares worth $136M. The largest sale was LinkedIn Corporation, an estimated $917M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Communication Services.
- Jennison Associates's largest Q1 2016 buy was Procter & Gamble: 1,657,581 shares worth $136M.
- Jennison Associates added most to Microsoft in Q1 2016, an estimated $424M increase.
- Jennison Associates's biggest Q1 2016 reduction was LinkedIn Corporation, cutting an estimated $917M.
- Jennison Associates fully exited Sherwin-Williams in Q1 2016, selling an estimated $292M.
- Jennison Associates's ten largest holdings make up 24% of its $95.3B portfolio in Q1 2016.
- Jennison Associates opened 56 new positions and closed 102 in Q1 2016.
- Jennison Associates's portfolio value fell 6.5% quarter-over-quarter to $95.3B.
Based on Jennison Associates's 13F filing for Q1 2016, filed 3 May 2016.